A Comparison of Outcomes of Treatment with Resection Prosthesis of the Hip in Revision and Oncological Surgery

Abstract

1.The use of the MUTARS modular resection prosthesis allows for fast clinical improvement that meets the patient's expectations both in oncological treatment and in revision arthroplasty. 2. The extent of bone resection, procedure duration and perioperative blood loss associated with the surgical placement of a resection prosthesis are similar in oncological treatment and in revision arthroplasty. 3. The use of a resection prosthesis in revision arthroplasty is associated with a high risk of implant dislocation.

Outcome after reconstruction of proximal femoral tumors: A systematic review

“…We reported the Musculoskeletal Tumor Society (MSTS) score to assess functional outcome as it was most commonly reported (23 studies reported the MSTS score). Only two studies reported the Toronto Extremity Salvage score, and six studies reported the Harris Hip score . The MSTS score is a clinician completed assessment rating six domains, resulting in a score of 0 to 100%, with a higher score indicating better function …”

MUTARS Prosthesis in Patients with Bone Cancer of Lower Limb: A Narrative Review of Functional Outcomes

“…In our review we included 10 full-text articles [1-4,6-10,12] and 2 papers [5,11] evaluated by title and abstract. The studies we selected were: eight retrospectives [1,2,4-8] and five prospective [3,[9][10][11][12].…”

“…Females are more represented than males in the considered papers, contrary to major epidemiological data. The types of bone tumors included in the studies are disparate, both in histological terms and primary or secondary nature: four papers [2,4,9,11] analyze only primary tumors, two articles study only metastatic lesions [5,8], while most studies collect data regarding both primary and secondary bone lesions [1,3,12]and the remaining articles don't report these informations [6,7,10]. Histological tumors reported are: metastatic bone tumors, osteosarcoma, leiomyosarcoma, chondrosarcoma, giant cell tumors, lymphomas and other primary bone tumors.…”

“…Regarding the site of MUTARS® implant, authors report prostheses replacement of the knee region [2,6,7,10,11], of the hip region [3,5,8], while the remaining articles consider multiple sites of the lower limbs affected by bone tumor [1,4,9,12]. The available evidence in literature, accord to which distal femur and proximal tibia are the most common site of bone tumors in lower limbs [13].…”

“…There are surgical outcomes as Henderson et al classification in three studied [1,2,6]; oncological outcomes as No Evidence of Disease (NED), Died With Disease (DWD) and Alive With Disease (DWD) used in four papers [1,2,6,7]. With regard to the aim of this research, the rehabilitation outcomes are so summarized: functional measures as Harris Hip Scale (HHS) in three studies [3,5,8], Harris Hip Scale Modified (m-HHS) in one study [3], Oxford Knee Score (OKS) in one article [7]; objective measures as gait analysis in two studies [10,12], stabilometry and Short Physical Performance Battery (SPPB) both in one study [12]; Visual Analogue Scale (VAS) for the subjective pain in four studies [3,5,8,12]; the range of motion (ROM) of the considered joint in four studies [6,7,10,12]; SF-36 questionnaire for quality of life in one study [10]. Some studies use functional measures specifically for this type of patients: Musculo-Skeletal Tumor Society score (MSTS) in 6 papers [1,4,5,[7][8][9][10][11][12], Karnofsky Performance Scale (KPS) in two studies [8,12], Enneking score in one study [4], Toronto Extremity Salvage Score (TESS) and Eastern Cooperative Oncology Group (ECOG) both in the same study [12].…”